parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones

International Journal of Antimicrobial Agents

Volumn 29, Issue 2, 2007, Pages 230-232

  Sun, Heather K ^a   Du, Xiaoli ^a   DeRyke, C Andrew ^a   Doern, Gary V ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; ASPARTIC ACID; CIPROFLOXACIN; ISOLEUCINE; LEVOFLOXACIN; MOXIFLOXACIN; PROTEIN PARE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VALPROIC ACID;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; DNA SEQUENCE; DRUG HALF LIFE; GENE; GENE AMPLIFICATION; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARE GENE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DNA TOPOISOMERASE IV; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; OFLOXACIN; QUINOLINES; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 33846092706     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.10.004     Document Type: Letter

References (11)

1. Richter S.S., Heilmann K.P., Beekmann S.E., Miller N.J., Rice C.L., and Doern G.V. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis 40 (2005) 225-235
2. Brueggemann A.B., Coffman S.L., Rhomberg P., et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 46 (2002) 680-688
3. Bast D.J., Low D.E., Duncan C.L., et al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother 44 (2000) 3049-3054
4. Florea N.R., Tessier P.R., Zhang C., Nightingale C.H., and Nicolau D.P. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid concentrations against Streptococcus pneumoniae. Antimicrob Agents Chemother 48 (2004) 1215-1221
5. Capitano B., Mattoes H.M., Shore E., et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 25 (2004) 965-973
6. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 14th edn. Approved Standard. Wayne, PA: NCCLS; 2004.
7. Brown S.D., Farrell D.J., and Morrissey I. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US study. J Clin Microbiol 42 (2004) 4980-4987
8. Davies T.A., Evangelista A., Pfleger S., Bush K., Sahn D.F., and Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob Agents Chemother 46 (2002) 119-124
9. Jorgensen J.H., Weigel L.M., Ferraro M.J., Swenson J.M., and Tenover F.C. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother 43 (1999) 329-334
10. Pestova E., Beyer R., Cianciotto N.P., Noskin G.A., and Peterson L.R. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob Agents Chemother 43 (1999) 2000-2004
11. Wright D.H., Brown G.H., Peterson M.L., and Rotschafer J.C. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 46 (2000) 669-683